Mainz: Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
- Groundbreaking Results Demonstrate Sensitivity for Colorectal Cancer of 97% with Specificity of 97% and Advanced Adenoma Sensitivity of 82%
- Results Exceed those from the Company’s European ColoFuture Clinical Study of the Same Design
- ColoFuture and eAArly DETECT Studies Support Inclusion of a Portfolio of Novel mRNA Biomarkers in Pivotal FDA PMA Clinical Trial (ReconAAsense); Trial is On Track to Commence Enrollment in Mid-2024
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.